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Abstract
Background: We report efficacy and safety outcomes from a prospective case series of 31 late-stage T.b. gambiense
sleeping sickness (Human African Trypanosomiasis, HAT) patients treated with a combination of nifurtimox and eflornithine
(N+E) in Yumbe, northwest Uganda in 2002–2003, following on a previously reported terminated trial in nearby Omugo, in
which 17 patients received the combination under the same conditions.
Methodology/Principal findings: Eligible sequential late-stage patients received 400 mg/Kg/day eflornithine (Ornidyl,
Sanofi-Aventis) for seven days plus 15 mg/Kg/day (20 mg for children ,15 years old) nifurtimox (Lampit, Bayer AG) for ten
days. Efficacy (primary outcome) was monitored for 24 months post discharge. Clinical and laboratory adverse events
(secondary outcome) were monitored during treatment. All 31 patients were discharged alive, but two died post-discharge
of non-HAT and non-treatment causes, and one was lost to follow-up. Efficacy ranged from 90.3% to 100.0% according to
analysis approach. Five patients experienced major adverse events during treatment, and neutropenia was common (9/31
patients).
Conclusions/Significance: Combined with the previous group of 17 trial patients, this case series yields a group of 48
patients treated with N+E, among whom no deaths judged to be treatment- or HAT-related, no treatment terminations and
no relapses have been noted, a very favourable outcome in the context of late-stage disease. N+E could be the most
promising combination regimen available for sleeping sickness, and deserves further evaluation.
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Introduction
Treatment of late-stage (meningo-encephalitic, stage 2) human
African trypanosomiasis (sleeping sickness, HAT) due to Trypano-
soma brucei gambiense currently relies on a meagre and very
problematic drug armamentarium, consisting of; (i) melarsoprol,
an old, extremely toxic[1] injectable, which in certain transmission
foci is ,70% effective[2] due to parasite resistance [3]; (ii)
eflornithine, a safer[4,5] and efficacious[4,6] drug (if given in a 14-
day standard regimen[7]) that must however be administered
intravenously with 24 hour nursing care, placing an additional
workload on the already fragile health systems in HAT-endemic
areas; and (iii) nifurtimox, an oral drug originally intended for
Chagas disease that is used on an off-label basis in HAT, but has
shown disappointing cure rates as a monotherapy[8]. Since no
new drugs are expected on the market for at least eight years[9],
combinations of these three drugs have long been considered the
way forward to maximise cure rates, lengthen the drugs’ lifespan
by preventing further parasite resistance, and possibly improve
safety and tolerability by reducing dosages of each partner drug,
which would also result in easier administration.
We previously reported[10] on a trial of the three possible
combinations, melarsoprol-nifurtimox, melarsoprol-eflornithine,
and nifurtimox-eflornithine (N+E), initiated in 2001 in Omugo,
Arua district, northwest Uganda, a historical HAT focus with high
rates of melarsoprol failure[11]. The trial (known as the Bi-
Therapy Trial or BTT) was interrupted on ethical grounds after
54 inclusions due to unacceptable death and severe adverse event
rates in the melarsoprol-containing arms, and authorisation from
the Uganda National Sleeping Sickness Control Programme to
switch to eflornithine as first-line gambiense HAT therapy in
Omugo, replacing melarsoprol. In this trial, the 17 patients
randomised to N+E experienced significantly better outcomes: no
fatalities or relapses, less frequent treatment interruptions, and
fewer, milder adverse events[10], clearly delineating a promising
new therapeutic avenue.
The trial was conducted within a long-established Me ´decins
Sans Frontie `res (MSF) programme offering standardised clinical
management, including a range of supportive therapies, the option
of second-line treatments for cases of relapse, and high follow-up
rates for discharged patients (in HAT, efficacy control visits are
conducted up to 24 months post treatment completion), thus
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experimental treatment. Furthermore, northwest Uganda was at
the time politically stable, facilitating long-term research. The
BTT provided evidence of the superiority of N+E in terms of
safety. Although efficacy results were not yet available, we
considered that further study of the N+E combination was
warranted, and, given the favourable study conditions in northwest
Uganda (a rarity for HAT-endemic settings), decided in mid-2002
to implement a case series study of N+E with the objective of
gathering more efficacy and safety data on this combination. We
opted against a multi-arm trial due to the much-decreased HAT
prevalence in the area and the imminent closure of MSF’s
programme, which would have jeopardised any attempt to reach
sufficient power for statistical comparisons, especially since a non-
inferiority design would have been needed to conclude N+E was at
least as safe and efficacious as the current perceived best option,
14-day eflornithine monotherapy.
In this paper, we report patient outcomes from this follow-up
study (conducted between September 2002 and March 2005, and
known as the NECS, or Nifurtimox-Eflornithine Case Series), and
provide a joint analysis of NECS and BTT patients treated with
N+E, to our knowledge the very first to receive this combination in
a research setting.
Methods
In mid-2002, the centre of HAT screening activities shifted from
Omugo, Arua district, to Yumbe District hospital, about 40 Km
northeast. Accordingly, the NECS study recruited patients
presenting to Yumbe hospital, on a sequential basis. Yumbe
district (pop. 253 000, 2002 census) borders Sudan. Most of the
district’s villages (rural communities scattered over thinly forested
savannah) reported HAT cases in the decade prior to the study
(MSF, unpublished observations).
We initially set a sample size of 153, enough to detect a cure rate
of 90% with 65% precision and 10% predicted incomplete follow-
up. However, the very low rate of passive HAT case detection, and
unexpectedly low HAT prevalence detected in active screening
sessions around Yumbe in late 2002, soon made this target
unlikely, a frequent problem in HAT studies due to the rapid
decline of transmission in sites where control activities are
implemented. We therefore decided pragmatically to carry on
recruitment until February 2003, corresponding with MSF’s
departure.
For consistency purposes, we replicated exactly the BTT trial
methods, detailed by Priotto et al.[10]. Briefly, non-pregnant
patients with bodyweight .10 Kg and late-stage T.b.gambiense
HAT, defined as microscopic evidence of infection in the
cerebrospinal fluid (CSF) or a CSF total leukocyte count of .5/
mL with trypanosomes detected in blood or lymph node fluid, were
invited to participate in the study if they had no history of HAT
treatment in the prior 24 months and if their follow-up could be
ensured.
After systematic deworming and antimalarial treatment,
patients received 400 mg/Kg/day eflornithine (Ornidyl, Sanofi-
Aventis) for seven days in six-hourly slow infusions, plus 15 mg/
Kg/day (raised to 20 mg for children ,15 years old) nifurtimox
(Lampit, Bayer AG) for ten days in three daily oral doses.
Clinically apparent adverse events were monitored on a daily
basis until discharge, and graded using Common Toxicity
Criteria[12]. Further safety measurements at baseline (day 0)
and discharge (day 11) included haemoglobin measurement,
thrombocyte and leukocyte (total and differential) counts, as well
as hepatic (alanine transaminase [ALT], bilirubin) and renal
(creatinine) function indicators (not done in BTT trial) measured
from serum by standard spectrophotometry. Parasitology was
repeated using standard techniques at discharge and 6, 12 and 24
months thereafter, and defaulters were traced.
Efficacy endpoints (the primary outcome) were failure in case of
(i) death within 30 days post treatment initiation or later if judged
compatible with HAT, or (ii) relapse within the 24 months of
follow-up based on parasites’ reappearance in any body fluid, or
an increasing CSF leukocyte count[10]; and cure for all other
patients followed up to and including the 24 month visit. Safety
endpoints (secondary outcome) consisted of the occurrence of
adverse events in temporal association with treatment, including
abnormal laboratory values. Anaemia was defined as hemoglobin
,13 g/dL (males) or ,11 g/dL (females) having decreased by
.20% from baseline; leukopenia as ,4000 leukocytes/mL and
decreased by .30% from baseline; neutropenia as ,2000
neutrophils/mL and decreased by .30%; bilirubin abnormality
as .17 mmol/L bilirubin and increased by .1.5 fold; ALT
abnormality as .12 UI/L ALT and increased by .2.5 fold; and
creatinine abnormality as .97 mmol/L (males) or .80 mmol/L
(females) creatinine and increased by .1.5 fold.
Analysis was done on Stata 9.0 software (Stata Corporation,
College Station, Texas). For comparability reasons, we adopted
efficacy estimate approaches used in previous HAT trials[13,14]:
(i) by intention-to treat (ITT: relapses and all deaths irrespective of
cause considered failures; lost to follow-up considered cured if they
were seen at least once and had not relapsed at the last visit); (ii)
per-protocol (only patients meeting all evaluability criteria retained
for analysis; only relapses and HAT-related deaths considered
failures); and (iii) a worst-case intention-to-treat scenario in which
all relapses, deaths and losses to follow-up are considered failures.
Below we provide findings for the NECS, the previously published
BTT N+E arm, and both groups combined. We abstained from
significance testing due to the low numbers in each group.
Both the BTT and the NECS studies received ethical clearance
from the Uganda National Council for Science and Technology,
and all participants (or their legal guardians) provided written
informed consent. ClinicalTrials.gov registration numbers are
NCT00330148 (BTT) and NCT00489658 (NECS).
Author Summary
African sleeping sickness (Human African Trypanosomiasis,
or HAT), due to the parasite Trypanosoma brucei gam-
biense, threatens millions across remote and conflict-
affected regions of sub-Saharan Africa, and causes about
15 000 reported cases every year. Untreated HAT pro-
gresses from stage 1 (infection of the blood and lymph) to
stage 2 (invasion of the central nervous system), and
ultimately death. Drugs for stage 2 are few. The historical
mainstay, melarsoprol, is highly toxic and inefficacious in
some areas due to parasite resistance. Eflornithine is the
only viable alternative, already established as safe and
efficacious, but difficult to administer and at risk of
resistance if used in monotherapy. This paper reports on
a series of 48 Ugandan patients treated with a novel
combination of nifurtimox (a drug registered for Chagas
disease) and eflornithine, 17 as part of a terminated trial,
and 31 in a subsequent case series study. Despite the low
sample size, findings are promising: no cases of treatment
failure, no treatment terminations, and no HAT- or
treatment-related deaths. Nifurtimox plus eflornithine
may be the best treatment hope for stage 2 HAT patients
in the next decade, while new drugs are developed. A
larger, multi-centric trial of the combination is ongoing.
Nifurtimox-Eflornithine for Sleeping Sickness
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Enrolment and follow-up
NECS recruitment lasted from October 2002 to February
2003. Out of 56 stage 2 HAT cases presenting to the hospital,
31 were eligible and included. Baseline characteristics (Table 1)
were broadly consistent with other stage 2 patients seen in
Yumbe during MSF’s intervention (data not shown). NECS
patients (n=31) compared well with the BTT group (n=17), but
a greater proportion had a low body mass index, they had
a higher geometric mean CSF leukocyte count (118/mL versus
46/mL), and typical sleeping sickness markers (insomnia,
somnolence and psychiatric signs) appeared more frequent,
suggesting that NECS patients were on average more clinically
advanced.
All 31 NECS patients were discharged alive. No deaths within
30 days of treatment start occurred, but two patients died before
the 6 month follow-up visit. A five-year old patient moved to
Sudan after the 6 month visit (during which he was found healthy
and parasite-free), and was subsequently lost to follow-up. The
remaining 28 patients completed all follow-up visits by March
2005 (Table 2).
Efficacy outcomes
No relapses were detected (Table 2). In the main ITT analysis,
the two deaths during follow-up were considered failures, while all
other patients were considered cured, giving an efficacy of 29/31
or 93.5% (Table 2). Because the two deaths were not HAT- or
treatment-related (see details below), per-protocol analysis con-
siders all patients as cured (efficacy 31/31 or 100%), while the ITT
worst-case scenario includes the patient lost to follow-up among
the failures, yielding an efficacy of 28/31 or 90.3%. Correspond-
ing efficacy estimates for the entire BTT+NECS series (n=48),
ranging from 91.7% to 100.0%, are shown in Table 2.
Safety and tolerability outcomes
The first dead patient, a 35 year old male, was attacked five
months after discharge while on a business trip to Sudan, and died
of his wounds at home shortly thereafter (he was reportedly
healthy before his trip). The second, a 37 year old female, had
been treated successfully for stage 1 HAT in Omugo in March
2000 (28 months before study enrolment), but was lost to follow-up
after one year. She experienced episodes of psychosis in April
2002, and was enrolled in the study in November. During
Table 1. Baseline characteristics.
Type BTT[10] (n=17) NECS (n=31) BTT+NECS (n=48)
nn n
Demographics
Female 10 58.8% 15 48.4% 25 52.1%
Mean age (range) 29.1 (9–62) 23.9 (4–45) 25.7 (4–62)
Mean weight (SD) 51.4 (8.4) 44.8 (15.1) 47.1 (13.4)
Mean body mass index (SD) 19.5 (1.8) 18.2 (2.2) 18.7 (2.1)
Body mass index,18.5 4 23.5% 17{ 58.6% 21{ 45.7%
Parasitology
Trypanosomes in lymph nodes 9 52.9% 18 58.1% 27 56.3%
Trypanosomes in blood 16 94.1% 24 77.4% 40 83.3%
Trypanosomes in CSF 10 58.8% 21 67.7% 31 64.6%
Leukocyte count in CSF
6–20 cells/mL 6 35.3% 5 16.1% 11 22.9%
21–99 cells/mL 5 29.4% 8 25.8% 13 27.1%
$100 cells/mL 6 35.3% 18 58.1% 24 50.0%
Clinical characteristics
Median hemoglobin (range), g/dL 11.5{ (9.0–17.0) 10.7 (8.7–12.7) 10.7{ (8.7–17.0)
Lymphadenopathy 10 58.8% 20 64.5% 30 62.5%
Headache 16 94.1% 28 90.3% 44 91.7%
Fever ($37.5uC) 6 35.3% 10 32.3% 16 33.3%
Pruritus 13 76.5% 22 71.0% 35 72.9%
Daytime somnolence 9 52.9% 23 74.2% 32 66.7%
Insomnia 0 0.0% 7 22.6% 7 14.6%
History of seizures 0 0.0% 1 3.2% 1 2.1%
Psychiatric signs 0 0.0% 10 32.3% 10 20.8%
Impotence or amenorrhea 2 11.8% 15 48.4% 17 35.4%
Arthralgia/myalgia 13 76.5% 20 64.5% 33 68.8%
{2 height values missing.
{6 missing values.
SD Standard Deviation.
doi:10.1371/journal.pntd.0000064.t001
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and drowsiness. Tracing staff performing a post-discharge home
visit found that she was being kept in chains by her family,
allegedly due to her psychotic behaviour; they also noted a wound
on her lower leg, reportedly caused by her imprisonment. After
inpatient treatment the wound improved, but once back home she
was again chained, the scar became infected and led to cellulitis;
her family did not bring her back for treatment and left her to die
of suspected septicaemia in February 2003. On balance, this death
is unlikely to be related to treatment (the patient was perfused in
the arms; deep tissue infections have been reported during
eflornithine infusions[5], but this cellulitis case was secondary to
a deep wound, and due to her family’s neglect). Her apparent
psychosis may be a HAT sequela, but pre-dates her participation
in the study.
The ratio of adverse events per patient was higher in the
NECS study than in the BTT: 4.0 (125/31) versus 2.1 (36/17).
Ascertainment of tremors, dizziness and vomiting/nausea
events, none of which major, was strikingly higher in the NECS,
and largely explained this difference (Table 3). On the other
hand, the ratio of major (Common Toxicity Criteria intensity 3 or
4) events per patient was similar (0.2 [7/31] versus 0.3 [5/17]),
and only one seizure was noted during the NECS treatment
period, compared to four in the BTT. All adverse events
resolved without ascertainable sequelae, and did not lead to
any treatment interruption in the NECS study, thus yielding only
one temporary suspension in the entire NECS+BTT cohort
(Table 3).
No biochemical adverse events were noted apart from one mild
case of raised creatinine at the end of the treatment course (1.6-
fold increase from baseline level). As spectrophotometry proce-
dures were only optimised mid-way through the study, reliable
ALT and bilirubin results are available for only the last 13 NECS
patients. Bilirubin levels appeared to decrease slightly (median
1.0 mg/dL at baseline versus 0.8 mg/dL at discharge) and ALT
remained constant (at 8 UI/L).
As in the BTT, post-treatment neutropaenia was a common
occurrence affecting 9/31 (29.0%) of patients, of which one had
a major episode (count,1000/mL; Table 3). These patients were
monitored clinically via home visits, but not re-tested after
discharge.
Discussion
The BTT and NECS studies represent the first experience with
a nifurtimox and eflornithine combination within a research
context. Though small and inconclusive, we believe these studies
represent a ‘proof of concept’ justifying further N+E experimen-
tation. Altogether, our group of 48 patients shows very promising
results: a favourable safety profile within the context of HAT, only
one temporary regimen interruption (in the BTT), no treatment-
or HAT-associated deaths, and no relapses in a setting where
melarsoprol failures exceed 30%. By comparison, case-fatality
rates among non-relapsing patients treated with melarsoprol were
4% (66/1596) in Omugo during 1996–2002, and 1% (1/93) in
Yumbe during 2000–2002 (MSF unpublished data). Among
adverse events, the high frequency of neutropaenia, already
highlighted during the BTT, was confirmed as a safety concern in
the NECS, although only one of the nine episodes was considered
major. In the two weeks following treatment, this could lead to
opportunistic infections that might not receive appropriate
treatment in remote HAT foci, especially among very advanced
stage 2 patients, who may already be immuno-compromised, and
among HIV-positives. Haematological and post-discharge moni-
toring of future N+E cohorts is thus warranted. Because the N+E
regimen we applied reduces the eflornithine dose by half, it might
nonetheless carry a lower risk of neutropaenia than eflornithine
monotherapy, unless a drug interaction exists. Neutropenia as well
as other bone marrow toxic effects affect 25–50% of patients
receiving eflornithine monotherapy[6], but the numbers followed
to date are small, and the clinical significance of such adverse
events has not been studied in the context of HAT.
Table 2. Efficacy endpoints and estimates.
BTT[10] (n=17) NECS (n=31) BTT+NECS (n=48)
Endpoints n % n % n %
died within 30 days of treatment start 0 0.0 0 0.0 0 0.0
died during follow-up{ 1 5.9 2 6.5 3 6.3
lost to follow-up 0 0.0 1 3.2 1 2.1
relapsed 0 0.0 0 0.0 0 0.0
cured at 24 months 16 94.1 28 90.3 44 91.7
Efficacy estimates n % (95%CI) n % (95%CI) n % (95%CI)
Intention-to-treat analysis
cured 16 94.1 29 93.5 45 93.8
patients in analysis 17 (71.3–99.9) 31 (78.6–99.2) 48 (82.8–98.7)
Per protocol analysis
cured 17 100.0 31 100.0 48 100.0
patients in analysis 17 (80.5–100.0){ 31 (88.7–100.0){ 48 (92.6–100.0){
ITT worst-case scenario
cured 16 94.1 28 90.3 44 91.7
patients in analysis 17 (71.3–99.9) 31 (74.2–98.0) 48 (80.0–97.7)
{none of the deaths were judged HAT- or treatment-related.
{one-sided confidence interval.
doi:10.1371/journal.pntd.0000064.t002
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Adverse Event type BTT[10] (n=17) NECS (n=31) BTT+NECS (n=48)
all major all major all major
Death 00 0
Neurological
Seizure 44 11 55
Confusion 10 31 41
Amnesia 00 10 10
Hallucinations 0 0 2 0 2 0
Coma 00 11 11
Tremors 00 1 3 0 1 3 0
Agitation 00 10 10
Dizziness 10 1 0 0 1 1 0
Drowsiness 00 10 10
Visual disturbance 0 0 3 0 3 0
Ataxia 00 11 11
Gastrointestinal
Anorexia 00 70 70
Abdominal pain 7 0 10 0 17 0
Diarrhea 40 50 90
Vomiting/Nausea 1 0 18 0 19 0
Weight loss$5% (major: $20%) 5 0 7 1 12 1
Cardiovascular
Arrythmia 00 10 10
Hypertension 3 0 3 1 6 1
Biological
Anemia 00 20 20
Leukopenia 10 10 10
Neutropenia 4 1 9 1 13 2
Thrombocytopenia n/a 0 0 0 0
Abnormal bilirubin (13 NECS patients only) n/a 0 0 0 0
Abnormal ALT (13 NECS patients only) n/a 0 0 0 0
Abnormal creatinin n/a 1 0 1 0
Other
Fever 30 70 1 0 0
Headache 10 00 10
Shivers 00 10 10
Myalgia/arthralgia 0 0 2 0 2 0
Chest pain 00 10 10
Infections 00 20 20
Epistaxis 00 10 10
Pruritus 10 00 10
Jaundice 00 70 70
Skin rash 00 20 20
Splenomegaly 0 0 1 0 1 0
Total adverse events 36 5 125 7 161 12
Patients suffering major events 5 5 10
Total treatment interruptions 1 0 1
Treatment suspension 1 0 1
Treatment termination 0 0 0
doi:10.1371/journal.pntd.0000064.t003
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combinations are available: a short-course regimen of eflornithine
plus melarsoprol had an efficacy of 93% for relapsing cases, with
two deaths among 40 patients[15], while in a melarsoprol-sensitive
focus of the Democratic Republic of Congo, among 69 patients
receiving a combination of melarsoprol and nifurtimox as part of
an equivalence trial, 14 treatment interruptions (12 suspensions
and two terminations), three deaths during treatment, and no
relapses were noted[8]. The latter trial also showed that even
a decreased dose of melarsoprol entailed a serious risk of life-
threatening encephalopathy, highlighting the urgent need to
discontinue first-line use of this toxic drug.
Limitations of the NECS study include the lack of a comparator
group, and possible ascertainment bias as regards certain mild
(intensity 1 and 2) clinical adverse events, leading to an over-
estimation of their frequency (moreover, under-ascertainment in
the BTT trial may also be possible). BTT patients were enrolled in
Omugo, and NECS patients in Yumbe: while these sites are
nearby (about 40 Km) and of similar environments, the two
patient groups may be systematically different. Baseline character-
istics of the two groups were broadly comparable, but NECS
patients may have been slightly more advanced (Table 1). Because
HAT is a very focalised disease, circulating strains in either site
may have been more virulent or more drug-resistant. Therefore,
interpretation of data for the entire BTT+NECS cohort merits
caution.
Clearly, the adoption of N+E as first-line treatment cannot be
predicated on the basis of these findings alone, although it could be
a viable alternative for relapsing cases, on a compassionate basis. It
is a sad reality in HAT that the paucity of research funds and
interest, compounded by arduous field research conditions, have
thus far led to very unconventional drug development pathways,
with little in the way of in vitro experimentation and dosage
optimisation, and very few completed, sufficiently powered and
comparative trials. The future looks somewhat brighter. In 2003,
a Good Clinical Practice equivalence trial of N+E versus standard
eflornithine was begun in the Republic of Congo by Epicentre and
MSF; the so-called NECT (Nifurtimox-Eflornithine Combination
Trial) has since become a multi-partner effort involving five other
enrolment sites, including two in Uganda. Most sites are currently
in the patient follow-up phase, and final results are expected in
2008–2009. Meanwhile, several interesting molecules are being
considered for stage 2 drug development[16]. As the prospects of
HAT elimination from Africa look unrealistic, such research is
greatly needed, and must receive greater attention from
researchers, funding agencies, and governments of both rich and
HAT-endemic countries.
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